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ABSTRACT 
Objective: The most common fungal infection, which is usually occurs in immunocompromised patients, is pulmonary cryptococcosis. Fluconazole 
(FLZ) is a first-generation triazole which is used for the treatment of pulmonary cryptococcal infection during 6-12 mo. A non-invasive and targeted 
medication delivery to lung is highly desirable due to lower delivered dose and reduced systemic effects. Large Porous Particles (LPPs) have shown 
lower phagocytic clearance and higher bioavailability compared to non-porous particles of the same size with a remarkable safety profile.  
Methods: In the present study, the effect of two different porogen agents with different mechanisms on FLZ loaded PLGA LPPs properties were 
evaluated using design expert software®. These properties included volume diameter, drug loading, encapsulation efficiency, mass median 
aerodynamic diameter (MAAD), geometric standard deviation (GSD) and fine particle fraction (FPF).  
Results: All FLZ-loaded PLGA LPPs (FLZ-PLGA LPPs) showed acceptable volume diameter, drug loading and encapsulation efficiency with rapid FLZ 
release due to macroporous structure. Significant differences in aerosolization properties in which MAAD, GSD and FPF optimized formulation of 
the optimized formulation were 6.71±0.4 µm, 1.65±0.08 and 33.20±1.7%, respectively.  
Conclusion: It was suggested that gas foamed preparation technique using ammonium bicarbonate was a better technique to produce FLZ loaded 
PLGA LPPs with more suitable in vitro respirable properties. 
Keywords: Fluconazole, Large porous particle, PLGA, Porogen, Pulmonary delivery 
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INTRODUCTION 
Lungs, skin and the central nervous system are the most sensitive organs 
which are affected by fungal infections very frequently. Pulmonary 
infection is commonly presented by cryptococcosis, coccidioidomycosis, 
histoplasmosis, or blastomycosis [1]. The incidence of invasive fungal 
infection has been increased over the past 30 y following expanded at-
risk patients’ population, including transplant receivers, patients who 
have HIV/AIDS or cancer, premature infants and elderly people [2]. The 
most common fungal infection which is usually occured in immune-
compromised patients is pulmonary cryptococcosis, which occurs due to 
the inhalation of some Cryptococcus species’ spores. Spores deposition in 
the alveoli may lead to lung infection [3]. 
Fluconazole (FLZ) is a first generation triazole with reduced 
lipophilicity which may be used to prevent and treat mucosal and 
invasive infections. FLZ is the most common medication for 
treatment of cryptococcosis and is still used clinically in spite of 
increasing isolated triazole resistance species. FLZ is recommended 
to treat acute and chronic pulmonary coccidiodomycosis. The 
recommended regimen contains oral fluconazole which lasts for 3-6 
mo. FLZ is also used for treatment of pulmonary cryptococcal 
infection for 6-12 mo [4]. Therapeutic agents may deliver to lung via 
oral, intravenous and pulmonary administration. Oral administration 
may lead to drug destruction by GI environment or first pass 
metabolism. Intravenous administration may cause drug accumulation 
in non-related organs or may lead to drug degradation during 
circulation. Previous reports indicated lung targeting of azoles would 
increase local therapeutic effect, minimize systemic exposure and side 
effects and thus risk of resistances [5]. Therefore, non-invasive and 
targeted medication delivery to lung is highly desirable due to the 
lower delivered dose and reduced systemic effects. 
Lungs special advantages including large surface area, extensive blood 
supply and high permeability, make pulmonary delivery a convenient 
non-invasive route of drug administration [6, 7]. Considering direct 
delivery of medications into the lung, aerosol therapy may be presented 
as the most effective treatment tool for lung diseases [8]. Commonly dry 
powder inhalers mass density is about 1±0.5 g/cm3 with the optimal 
particle size range of 1–5μm. However, this geometric size is ideal for 
alveolar macrophage phagocytosis, which reduces aerosols residence 
time in the lungs [9, 10]. Alveolar macrophages phagocytosis of highly 
large porous particles (LPPs) with low density (ρ<~0.4 g/cm3) can be 
significantly diminished and may enhance particle residence time in 
deep lung [11, 12]. Porous PLGA particles showed remarkable safety 
profile owing to their compatibility in the human body [13]. In addition, 
it has been proved that PLGA LPPs could escape macrophage uptake, 
which leads to efficient delivery of inhaled medicine for long periods of 
time [14]. Therefore, LPPs have shown better bioavailability compared 
with non-porous particles of the same size [12, 15, 16]. 
Poly lactic-co-glycolic acid (PLGA) is a biodegradable, biocompatible and 
non-immunogenic synthetic polymer which has been approved by FDA 
for therapeutic targets and is mostly applied among synthetic polymers 
[17, 18]. To obtain an ideal treatment with lower side effects, it is better 
to administer high concentrations of therapeutic agents to the target 
organ directly and continuously [19]. Different typical methods, 
including gas foaming, porogen leaching and phase separation, are used 
to generate porous structures in polymer matrices, including 
microparticles [9]. Porogen leaching method is the most widely used 
technique with a variety of particulate porogens, such as salts. 
Effervescent salts, including ammonium bicarbonate are gas-evolving 
salt porogens which cause carbon dioxide and ammonia gas bubbles 
vibrant evolution in PLGA structure and produce large porous PLGA 
scaffolds [20]. Accordingly, pulmonary delivery as an attractive and non-
invasive route of administration was chosen for fluconazole LPPs in 
order to obtain better deposition in the lungs. The objective of this study 
was to prepare and evaluate inhalable PLGA FLZ-LPPs as a suitable 
carrier for local delivery into deep lungs using two different pore-
forming techniques.  
MATERIALS AND METHODS 
Chemicals 
Fluconazole (FLZ) was received as a gift from Alhavi (Iran), PLGA 
Resomer® RG502H (lactide: glycolide 50:50, carboxylate end group, 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 12, Issue 4, 2020 
Ahmadi et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 258-263 
259 
inherent viscosity: 0.18 dl/g) was supplied from Boehringer Ingelheim 
(Germany), Poly Vinyl Alcohol (MW 72000, 97.5-99.5 mol% hydrolysis) 
was purchased from Fluka (Sweden). Sodium chloride (NaCl), 
Ammonium bicarbonate (ABC) and Dichloromethane (DCM) were 
purchased from Merck (Germany).  
Fluconazole analysis  
FLZ absorbance was scanned at 200-400 nm range using a 
spectrophotometer (T80 UV-Vis spectrophotometer (Germany). The 
maximum wavelength was selected for analysis of Fluconazole. 
Fluconazole analysis validation 
Two calibration curves were plotted for the determination of FLZ 
concentration (12.5-200 µg/ml) in two different media (phosphate 
buffer solution and acetonitrile: water solution). Linearity, inter-day 
and intra-day precision and accuracy of curves were determined for 
analytical curve validation [21]. All concentrations were prepared in 
three different days. Each concentration was tested in triplicate. 
Preparation of FLZ-LPPs 
FLZ-LPPs were prepared using a modified double emulsion 
method[20]. PLGA and FLZ (1:1 and 1:2 ratio) were dissolved in 1 
ml dichloromethane. Two different porogens were freshly-prepared 
in their optimized concentration (ABC 1.5% w/v and NaCl 0.5%w/v 
aqueous solution) and added to the polymer solution. The resulting 
mixture was sonicated in ice bath for 30s to form a w/o emulsion 
which was further homogenized in PVA solution (0.5% w/v). The 
final w/o/w emulsion was added to 5 ml water and stirred 
overnight at room temperature to remove DCM. The LPPs were 
collected by centrifugation at 4000 rpm for 15 min, washed 3 times 
with distilled water and were lyophilized in mannitol 2%. 
Considering our previous study, two variable factors were selected for 
design of the experiment. LPPs were prepared applying 2-level full 
factorial experimental design using Design expert 10VR software (table 
1). Six different responses (volume diameter, drug loading, 
encapsulation efficiency, Mass median diameter (MMAD), Geometric 
standard diameter (GSD) and Fine particle fraction (FPF) were examined 
to obtain the most acceptable formulation for pulmonary delivery. 
Solid-state study 
Differential Scanning Calorimetry (DSC) was used to study the solid 
state of prepared LPPs. The thermograms of Blank-LPPs, FLZ and 
FLZ-LPPs were obtained using DSC BAHR thermoanalyzer (Gmbh, 
Germany). Samples were weighed and placed in sealed aluminum 
pans and heating was performed under a flow of nitrogen gas in the 
range of 25 to 250 °C at a rate of 10 °C/min. 
Characterization of FLZ-LPPs 
Particle shape and size 
Particles shape was analyzed using a light microscope. Mean volume 
diameter of the FLZ-LPPs was measured by Shimadzu particle size 
analyzer (SALD 2101, Japan).  
Drug loading and encapsulation efficiency 
To determine drug loading and encapsulation efficiency, 5 mg FLZ-LPPs 
were dissolved in DCM and FLZ was extracted using a mixture of water 
and acetonitrile. Solvents were evaporated under nitrogen flow [10, 22]. 
FLZ was determined using a validated analysis method. All assays were 
done in triplicate. Drug loading and encapsulation efficiency were 
calculated using equations which were mentioned previously. 
In vitro release profile 
5 mg of FLZ-LPPs were suspended in a tube containing 10 ml 
phosphate buffer solution (pH, 7.4). Samples were shaken vertically 
at 100 rpm, 37 °C. At determined time intervals, samples were 
withdrawn, diluted with acetonitrile and water mixture and 
centrifuged at 15000 rpm for 10 min. FLZ amount in the supernatant 
was determined using validated analysis method. The release 
studies were done in triplicate.  
In vitro inhalation properties 
FLZ-LPPs powder aerosolization properties were analyzed at room 
temperature using a 7-stage NGI cascade impact or (Copley 
Scientific, UK) connected to a Copley HCPS pump, while the airflow 
rate was set at 30 L/min. 10 mg FLZ-LPPs was delivered into the NGI 
using a spin haler for every run. Every sample was tested in 
triplicate. Drug solution was recovered from each collection cup and 
the amount of the active ingredient in each cup was determined 
using validated analysis method. Copley Inhaler Testing Data 
Analysis Software (CITDAS) was used to determine MMAD, GSD and 
FPF based on drug collected on stages 1–7 and micro-orifice 
collector (MOC) [23]. 
Statistical analysis 
One-way ANOVA statistical test was used to assess the significance 
of the differences between the various groups. Multiple comparison 
Tukey test was used to compare the means of different treatment 
groups and P<0.05 was considered to be statistically significant. 
RESULTS AND DISCUSSION 
Fluconazole analysis  
The maximum wavelength selected for analysis of FLZ was 260 nm.  
Analysis method validation 
Two different calibration curves were plotted and validated for in 
vitro release (phosphate buffer media), and determination of 
loading, encapsulation efficiency and aerosolization properties 
(acetonitrile/water media). The validation parameters including 
linearity (regression equation, correlation coefficient), inter-day, 
intra-day precision and accuracy were reported in table 1 which 
represented a linear standard calibration curve with acceptable 
accuracy and precision in both experimented media. 
Preparation of FLZ-LPPs 
Production of controlled size porous particles using porogens has 
been challenging in recent years. The commonly used technique for 
the production of PLGA-based particles is double emulsion-solvent 
evaporation technique which forms an internal and external osmotic 
pressure difference in the aqueous phases of the emulsion [24]. 
Polymer/solvent mixture in which porogen salts is embedded forms 
pores while salts are leached out after solvent evaporation [20]. In 
particle hardening step, osmogens presence in the internal aqueous 
phase may cause water influx from the external aqueous phase to 
internal phase during solvent evaporation, which will form porous 
particles [24]. Sodium chloride (NaCl) has been used as the osmogen 
previously. Different concentrations of NaCl in the internal and 
external aqueous phases may cause different osmotic pressure on 
the produced microparticles [13]. Previous reports indicated that 
NaCl was practically an unsuitable agent for the production of PLGA 
LPPs using double emulsion solvent evaporation technique mainly 
because of its negative effect on primary emulsion stability [24]. 
Effervescent based (gas-foamed) techniques are alternative 
strategies for PLGA LPPs production. In these techniques, an 
effervescent material such as ammonium bicarbonate is 
decomposed into carbon dioxide and ammonia during emulsification 
and can form a porous matrix as the carbon dioxide gas escapes[25]. 
Two variable factors, porogen type and FLZ amount were selected 
for different formulations by. FLZ loaded PLGA LPPs were prepared 
applying a double emulsion solvent evaporation method. A 2-level 
full factorial experimental design (Design expert®) was used to 
evaluated six responses, which were explained in table 2. 
  
Table 1: Analytical curves validation results 





Phosphate buffer y=0.0033x-0.0076 0.9997 97.4±3.3 91.3±4.3 97.7±2.3 
Water/Acetonitril y=0.0019x-0.0112 0.9994 98.6±1.4 98.3±2.3 94.7±3.2 
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Table 2: Factors, factor levels and responses in 2-level full factorial experimental design 
Factors Type of factors Factors level Response  
X1 Porogen type ABC NaCl Y1 Drug loading% 
X2 Fluconazole (mg) 10 20 Y2 Encapsulation efficiency% 
    Y3 Volume diameter (micron) 





As it can be seen in fig. 1, FLZ showed an endothermic melting 
point at 147.5 ⁰C (C). Blank PLGA LPPs showed an endothermic 
peak at 162.6 ⁰C (a). FLZ-LPPs showed both endothermic peaks at 
152.3 and 163.9 ⁰C. Blank PLGA LPPs showed an endothermic 
peak at 162.6 ⁰C which is seen in FLZ-LLPs thermogram with a 
little increase in melting point at 163.9 ⁰C. DSC thermograms in fig. 
5 indicated that the free FLZ endothermic peak at 147.5 ⁰C is seen 
in FLZ-LPPs with a little increase in melting point at 152.3 ⁰C. 
Considering no new peak appearance or existing peak 
disappearance, it was confirmed that FLZ was intact during the 
preparation process and its structure was not destroyed and was 
incorporated into PLGA LPPs intact. 
  
 
Fig. 1: DSC thermograms of blank-LPPs (a), FLZ-LPPs (b), FLZ (c) 
 
Characterization of FLZ-LPPs 
Particle shape and size 
Microscopic image of non-freeze dried FLZ-LPPs is seen in fig. 2 in two 
different scales. As routine non-freeze dried FLZ-LPPs size was less 
than freeze-dried FLZ-LPPs. Microscopic images could support particle 
size data obtained from particle size analyzer. Volume diameter (dv) of 
FLZ-LPPs was in the range of 11-16 µm (table 3). Volume diameter 
(dv) of FLZ-LPPs was in the range of 11-16 µm. As it is comparable 
with reported particle size in table 3, FLZ-LPPs particle size in F2 was 
smaller than F4 but showed higher polydispersity. Particles porosity 
has been reported by SEM in previous publications [13]. Considering 
Deign expert software, there was no significant difference (p>0.05) in 
volume diameters of FLZ-LPPs and all particles were in an acceptable 
range for pulmonary delivery. Results were in consistency with 
previous reports on PLGA LPPs [24]. 
  
 
Fig. 2: Microscopic images of non-freeze dried FLZ-LPPs F2 (left), F4 (right), Bar= 10000 nm 
 
Drug loading and encapsulation efficiency 
Drug loading and encapsulation efficiency for FLZ-LPPs were 
reported in table 3. Statistical analysis showed that there was no 
significant difference between drug loading and encapsulation 
efficiency of F1 to F4 formulation. Drug loading and encapsulation 
efficiency of F1 to F4 formulation were the same. No significant 
difference was reported between them. Poor drug encapsulation 
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efficiency control owing to drug loss between the two phases during 
particle hardening is the major limitation of osmogen-based 
technological approach. Previous studies reported higher drug 
encapsulation efficiency for highly porous PLGA particles since gas-
foamed techniques pore formation depends on effervescence rather 
than diffusional mass exchanges between aqueous phases [24, 25] 
Hereby, our results indicated that there was no significant difference 
in drug loading and encapsulation efficiency of all formulations 
(p>0.05) and both groups showed low drug loading efficiency which 
may be related to large surface area of highly porous particles [9]. 
  
Table 3: FLZ-LPPs characterization results 
 Porogen type Fluconazole (mg) Dv DL% EE% 
F1 NaCl 10 16.2±2 11.6±0.15 35±0.45 
F2 NaCl 20 13.80±1.06 12.2±0.34 24±0.68 
F3 ABC 10 15.81±0.82 11±0.51 33±1.53 
F4 ABC 20 11.5±0.32 15.3±0.87 31±1.73 
Dv: Volume diameter, DL%: Drug loading%, EE%: Encapsulation efficiency% 
 
In vitro release profile 
Fig. 3 compares in vitro release profiles of different FLZ-LPPs. In 
vitro release profile showed that FLZ was released completely from 
F2 and F4 formulations after 4 and 6 h while F1 and F3 released FLZ 
within 8 h. In vitro release profiles of different FLZ-LPPs showed a 
burst release within the first hour was predictable for all PLGA FLZ-
LPPs, since porous microparticles may release drugs faster than 
their solid equivalents, in the same size (Rivera, Martinez-Oharriz et 
al. 2004). Polymer nature may affect FLZ release from FLZ-LPPs. 
Therefore, the FLZ fast release is related to higher hydrophilicity of 
PLGA 502H comparing to other PLGA polymers [26]. Drug release in 
porous microparticles shows faster rate than their solid equivalent 
in given particle size, considering lower resistance to drug diffusion 
in porous microparticles [27]. Hence it is obviously predictable that 
in vitro drug release profile of PLGA LPPs would be faster owing to 
their larger surface area [9]. As it can be seen in fig. 3, higher burst 
release of formulations F2 and F4 may be related to higher surface 
adsorbed fluconazole due to the presence of higher initial 
fluconazole amounts [28, 29]. A rapid drug release due to the 
macroporous structure of the system is the main drawback of 
osmogen-based approach [24, 25]; therefore, it can explain the 
reason of faster release in F1 versus F3.  
 
Fig. 3: In vitro release profile of FLZ-LPPs. Data represents 
mean±SD, (n=3) 
 
Possible release kinetics of FLZ-LPPs were evaluated and reported 
in table 4. Considering higher r2, Higuchi was the best-fitted model 
for FLZ-LPPs. Considering higher r2, the Higuchi model was the best-
fitted model for all FLZ-LPPs. 
 
Table 4: Release kinetic R-square results (n=3) 
 Zero First Higuchi 
F1 0.8875 0.9537 0.9999 
F2 0.9586 0.9566 0.9999 
F3 0.9559 0.905 0.9856 
F4 0.9386 0.9811 0.9962 
 
In vitro inhalation properties 
Aerosol critical parameters including MMAD, GSD and FPF of FLZ-LPPs 
were summarized in table 5. MMAD of all formulations were in an 
acceptable range, while GSD showed upper limit amounts except for F4. 
Fig. 4 shows the in vitro lung distribution of FLZ-LPPs. Considering 
design expert® software, three responses (MMAD, GSD and FPF) of 
FLZ-LPPs were significantly different (p<0.05) in F1-F4 
formulations. Critical aerosol parameters, including MMAD, FPF and 
GSD represent particles aerosolization efficacy [30]. The optimum 
aerodynamic diameter for aerosols is 1–5 μm. Slow settling in 
smaller particles leads them to be exhaled, while larger particles 
deposit in the oral cavity or upper airways, which causes their 
simple clearance [30]. FPF represents the respirable aerosols which 
are able to deposit in pulmonary tract. Consequently, the deeper 
lung deposition requires the higher FPF [31]. The ratio of particles 
with diameter at the 84.1% cumulative percentage to the 50% is 
defined as GSD and its acceptable range is 1.3–3.0 [32]. 
Aerosolization properties of all FLZ-LPPs were determined and 
reported in fig. 5. F1 and F4 showed MMAD a little more than 
acceptable range while F2 and F3 were in the range. GSD of all 
formulations was out of range except for F4. The FPF was in the 
range of 33-74%. Results indicated that for both porogens, FLZ 
amount significantly affected MMAD of FLZ-LPPs but in a reverse 
mode. For NaCl, higher fluconazole FLZ amount and for ABC lower 
FLZ amount produced FLZ-LPPs with smaller and more acceptable 
MMAD. For GSD and FPF this is quite opposite which means for NaCl, 
lower FLZ amount and for ABC higher FLZ amount produced FLZ-
LPPs with smaller and more acceptable GSD. Considering previous 
reports, ammonium bicarbote is a better porogen comparing NaCl, 
since NaCl may form a higher viscous solution due to the interaction 
of inorganic salts with PVA which leads to form aggregates and gel 
by salting out [33, 34]. 
  
Table 5: FLZ-LPPs aerosolization properties 
 MMAD GSD FPF% 
F1 6.49±0.37 3.19±0.21 36.42±0.53 
F2 2.91±1.37 6.62±0.79 74.01±3.09 
F3 2.62±0.04 7.71±0.17 51.66±4.73 
F4 6.71±0.39 1.65±0.08 33.20±1.69 
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Fig. 4: Aerosol assessment profile of FLZ-LPPs (n=3) 
 
 
Fig. 5: Interaction plot of MMAD (left), GSD (middle) FPF(right) as dependent parameters (n=3) 
 
Interaction plots and statistical analysis results of design 
expert®software for aerosolization properties, including MMAD, GSD 
and FPF were presented in fig. 5 and table 6. 
Considering software, "Adeq Precision" measures the signal to 
noise ratio. A ratio greater than 4 is desirable, which indicates that 
the model can be used to navigate the design space. All three 
responses ratio (MMAD, GSD and FPF) indicate adequate signals. 
The "Pred R-Squared" less than 0.2 is in reasonable agreement 
with the "Adj R-Squared". The coded equation is useful for 
identifying the relative impact of the factors by comparing the 
factor coefficients. As it is shown in equations, MMAD, GSD and 
FPF were dependent to both factors; porogen type and fluconazole 
amount. 
 
Table 6: FLZ-LPPs significant responses analysis of variance (A: Fluconazole amount, B: porogen type) 
 MMDA GSD FPF 
p-value prob>F 0.0014 0.0304 0.0299 
R-Squared 0.9972 0.9401 0.9412 
Adj R-Squared 0.9959 0.9102 0.9118 
Pred R-Squared 0.9890 0.7605 0.7647 
Adeq Precision 38 7.925 8 
Equation 4.7+1.9*AB 4.63-2.17*AB 45.5-10*AB 
 
CONCLUSION 
FLZ-PLGA LPPs were prepared using a simple and efficient w/o/w 
emulsion containing an effervescent porogen. The optimized FLZ-
PLGA LPPs (F4) showed suitable aerosolization properties, with 
Higuchi matrix controlled diffusion release kinetics of fluconazole. 
Aerosolization properties of F4 were suitable and may confirm in 
vivo efficacy of FLZ-PLGA LPPs in further studies. It confirms the 
higher efficiency of ABC as the porogen agent for PLGA LPPs. 
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